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It has been suggested that low density lipoprotein-containing circulating immune complexes (LDL-CIC) play a role in atherogenesis
and are involved in the formation of early atherosclerotic lesion. These complexes, as well as anti-LDL autoantibodies, have been
found in the blood and in the atherosclerotic lesions of patients with different cardiovascular diseases, as well as in the blood of
animals with experimental atherosclerosis. It can be suggested that the presence of anti-LDL antibodies in the blood is a result
of immune response induced by lipoprotein modification. LDL-CIC differs from native LDL in many aspects. It has much lower
sialic acid content, smaller diameter, and higher density and is more electronegative than native LDL. Fraction of LDL-CICs is
fundamental to the serum atherogenicitymanifested at the cellular level. LDL-CIC, unlike native LDL, is able to induce intracellular
accumulation of neutral lipids, especially esterified cholesterol, in cells cultured from uninvolved human aortic intima and in
macrophage cultures. After removal of LDL-CIC, the CHD patient’s sera lose their atherogenic properties. Titer of LDL-CIC in
blood serum significantly correlateswith progression of atherosclerosis in human in vivo andhas the highest diagnostic value among
other measured serum lipid parameters. Elevated CIC-cholesterol might well be a possible risk factor of coronary atherosclerosis.
1. Introduction
Widely spread clinical manifestations of atherosclerosis such
as coronary heart disease (CHD), cerebrovascular stroke,
renovascular hypertension, and violation of the lower limbs
vascular permeability, are the result of formation of advanced
atherosclerotic lesions in a vascular wall. A trigger mech-
anism for the development of atherosclerotic lesions is an
intracellular lipid deposition and subsequent foam cell for-
mation with excessive production of connective tissue matrix
components and, possibly, cellular proliferation and inflam-
matory reactions [1, 2]. Atherosclerosis can be generally
described as an excessive fibrofatty, proliferative, inflamma-
tory response to damage of the artery wall, involving several
cell types, such as smooth muscle cells, monocyte-derived
macrophages, lymphocytes, and platelets [3]. During the last
three decades, the autoimmune hypothesis of atherosclerosis
was developed and the evidence for an important role
for autoantibodies against modified low density lipoprotein
(LDL) and LDL-containing circulating immune complexes
(LDL-CIC) in atherogenesis has been accumulated. Immuno-
logical factors appear to contribute to the development of
atherosclerosis as many other factors including alterations
in plasma lipid and lipoprotein levels, platelet function,
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clotting factors, arterial smooth muscle cell metabolism, and
blood pressure regulation. In a number of recent studies it
has been suggested that the presence of LDL-CIC in the
blood promotes the onset and development of atherosclerotic
lesions in the vessel wall. It has been demonstrated that
modified LDL and especially LDL-CIC act as the primary
agents responsible for excessive cholesterol accumulation in
vascular cells [4–9]. The atherogenic properties of LDL-
containing immune complexes suggest them as a candidate
marker for atherosclerosis.
2. LDL-CIC and Its Physicochemical
Characteristics
Anti-LDL autoantibodies were first detected in the blood
of patients with hyperlipidemia accompanied by myeloma
or/and ischemic heart disease [10]. In 1965, Beaumont [11]
described a situation in which hyperlipidemia, xanthomato-
sis, and atherosclerosis were apparently associated with anti-
𝛽-lipoprotein antibodies. The antibodies against lipoproteins
or LDL-binding factors were found in the blood of patients
suffering from various vascular diseases as well as in healthy
subjects [12]. Bauer et al. established that immunoglobulins
are the major LDL-binding proteins in human plasma [13].
The emergence of anti-LDL autoantibodies in the blood
implies that lipoproteins can be regarded as autoantigens.The
high immunogenicity and ability of homologous chemically
modifiedLDL to generate antibodies have been demonstrated
[14]. The discovery of autoantibodies in modified LDL in
the blood of patients therefore seems natural. Autoantibodies
against glycosylated LDL were detected in the blood of
patients with diabetes mellitus [15]. Autoantibodies specific
for malondialdehyde-modified LDL have been found in the
blood of healthy subjects and patients with coronary artery
disease, as well as in the blood of experimental animals [16].
Deposits of the immune complex components were found
in vascular atherosclerotic lesions [17–19]. Autoantibodies of
immunoglobulin G class against modified LDLwere detected
in the blood of patients with angiographically assessed
coronary atherosclerosis [2, 12, 20–23]. In healthy subjects,
the level of anti-LDL autoantibodies was considerably lower
than that in atherosclerotic patients [2].These autoantibodies
exhibit a high affinity for desialylated LDL (neuraminidase-
treated LDL) and for malondialdehyde-modified LDL. They
have a lower affinity for native, oxidized, glycosylated, and
acetylated LDL, as well as for LDL, which has undergone
other chemical modifications.The higher affinity of autoanti-
bodies for modified LDL compared with native LDL suggests
that the antibodies are produced in vivo in response to the
appearance of modified LDL in the blood [24, 25].
Antibodies against LDL modified with malondialdehyde
(MDA) have been detected in the blood of animals with
experimental atherosclerosis and in atherosclerotic lesions
in humans [25–28]. Even though elevated levels of oxidized
lipids, such as MDA and F
2
-isoprostanes, have been found
in the blood of subjects with CHD [29, 30], there is some
evidence that oxidized lipids do not accumulate in noticeable
amounts in human LDL since high density lipoproteins seem
Table 1:Theproperties of LDL from circulating immune complexes.
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to detoxify and/or transfer them from the circulation to
the liver [31]. On the other hand, electronegative LDL [32],
small/dense LDL [33], and desialylated LDL differing from
native LDL by lowered sialic acid content [2, 34, 35] were
found in the blood of patients with coronary atherosclerosis.
It can be suggested that the presence of anti-LDL antibod-
ies in the blood is a result of immune response induced by
lipoproteinmodification. Tertov et al. [36] isolated circulating
immune complexes from blood serum using polyethylene
glycol 6000 and have found that LDL-CIC differs from
native LDL in many aspects (Table 1). Specifically, it has
low sialic acid content; that is, it is desialylated LDL. The
neutral lipid and phospholipid contents of LDL-CIC are
considerably lower than those in native LDL. Particles of
LDL-CIC have a smaller diameter and higher density. The
higher electrophoretic mobility shows that LDL-CIC is more
electronegative than native LDL. Finally, LDL-CIC, unlike
native LDL, is able to induce intracellular accumulation
of neutral lipids, especially esterified cholesterol, in cells
cultured from uninvolved human aortic intima. Thus, it was
shown that LDL-CIC is quite similar to themultiple-modified
(desialylated) LDL described earlier [37–39]. There was a
strong correlation between the LDL content in circulating
immune complexes and blood concentration of desialylated
LDL but not of total LDL. This suggests that predominantly
desialylated LDL forms complex with autoantibodies and
proves that the affinity of circulating anti-LDL autoanti-
bodiesis higher for desialylated LDL than for native LDL
[36]. Moreover, anti-LDL autoantibodies bind much more
effectively with LDL of patients having a high percentage of
desialylated LDL than with LDL of healthy subjects having
a low content of desialylated LDL [40]. Desialylated LDL
has certain modifications that could stimulate the immune
response: alterations in carbohydrate composition and in the
tertiary structure of apo B, modification of lysine amino
groups, and aggregation of lipoprotein particles [38, 39].
3. Atherogenicity of LDL-CIC
The investigation of proatherogenic role of LDL-CIC has
started long ago, and it seems relevant to look into historical
perspective to revive the interest in this topic.The first experi-
mental data on the effect of LDL and anti-LDL autoantibodies
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on cell metabolism were reported by Beaumont’s group as far
as in 1979 [41]. It was found that incubating cultured fibrob-
lasts with LDL, forming immune complexes with antibodies,
facilitated intracellular cholesterol accumulation.
Klimov et al. have demonstrated thatmousemacrophages
cultured in the presence of immune complexes containing
LDL and rabbit anti-human LDL antibodies demonstrated
an increased uptake of LDL [42]. They have also shown that
incubation of human peritoneal macrophages with autolo-
gous LDL-containing immune complexes causes transforma-
tion of macrophages into foam cells [38].
Griffith et al. [43] have found that human macrophages
incubated in vitro with insoluble LDL-containing immune
complexes accumulate cholesterol and are transformed into
foam cells.
It should be mentioned that the LDL of immune com-
plexes amounts to not more than 2% of the total circulating
LDL pool [4, 5]. However, this LDL fraction is fundamental
to the serum atherogenicity manifested at the cellular level.
In a cell culture, immune complexes isolated from the serum
cause atherosclerosis-related changes similar to those caused
by the whole serum [4, 5]. There is a direct correlation
between the LDL content of circulating immune complexes
and serum atherogenic potential [4].
Orekhov et al. [44] have shown that insoluble immune
complexes containing LDL and heterologous anti-LDL anti-
bodies induce lipid accumulation in cultured cells.The ability
of antibodies to stimulate lipid accumulation was found to
be dependent on the LDL content of the immune complex
[44]. It was also shown that the atherogenic potential of
desialylated LDL isolated from the blood of atherosclerotic
patients is markedly increased if the LDL forms an immune
complex with autoantibodies [2].The addition of desialylated
LDL and anti-LDL autoantibodies to cultured human aortic
smooth muscle cells enhanced the intracellular cholesterol
accumulation considerably [2, 45, 46]. Native LDL that did
not induce intracellular cholesterol accumulation became
atherogenic after interaction with autoantibodies (i.e., the
LDL acquires the ability to increase the cholesterol content of
cultured cells) [2, 45, 46]. Interaction of LDL with anti-LDL
autoantibodies considerably increases the uptake (binding
and internalization) of the lipoprotein by arterial cells, which
may account for the stimulating effect of antibodies on the
LDL-induced accumulation of intracellular cholesterol [2].
After being added to a cell culture together with antibodies,
fibronectin and Clq complement component (which are the
constituents of an immune complex) increase the LDL uptake
to a greater extent than the antibodies added alone.This leads
to a massive cholesterol accumulation [2].
It was demonstrated that removal of IgG and IgM as well
as circulating immune complexes from atherogenic sera of
CHD patients leads to a partial or complete elimination of
their atherogenic properties (i.e., its ability to induce intra-
cellular lipid accumulation). Removal of immunoglobulin G
caused the greatest fall in the serum atherogenicity; the fall
was lower after removal of immunoglobulin M, and athero-
genicity remained virtually unchanged after immunoglobulin
A removal [3]. These facts lead to the suggestion that the
majority of the atherogenic LDL of an immune complex is
bound with antibodies of the immunoglobulin G class; there
is no evidence that IgG-containing LDL-CIC may be more
atherogenic and those results only allow assuming that just
IgG and, in lesser extent, IgM but not IgA participate in
LDL-CIC formation. At the same time, circulating immune
complexes (CIC) isolated from these sera brought about
accumulation of cholesterol in cultured SMC of unaffected
human aortic intima. The ability of atherogenic sera to
stimulate the accumulation of intracellular cholesterol cor-
related with the cholesterol level in the CIC isolated from
these sera. The cholesterol content in CIC isolated from sera
of CHD patients, which displayed atherogenic properties
in culture, was characterized by an elevated cholesterol
level in CIC (33.2 ± 1.2 pg/mL) significantly (𝑃 < 0.01)
different from the values seen in the group of healthy donors.
Neither of the nonatherogenic sera had an elevated CIC-
cholesterol level.These findings suggest that inmost cases the
cholesterol-containing immune complexes are responsible
for the atherogenic properties of the serum [3]. Basing on the
knowledge of the absence of atherogenicity of native LDL, it
can be suggested that nonmodified LDL does not produce
an immune response, and for the formation of LDL-CIC
lipoprotein particles should be modified in some way; apo-
B desialylation may act as one of the mechanisms of LDL
immunogenic modification. At the same time, it is unknown
whether LDL-CIC contain only modified LDL, or also native
LDL; the last is possible due to common immunoglobulin-
binding sites, which may be present in both native and
modified LDL.
The mechanisms of intracellular lipid accumulation
caused by LDL-CIC obviously are an area that needs further
investigation. There is evidence that immune complexes
formed between modified LDL as antigens and IgG autoan-
tibodies may modulate the inflammation in atherosclerosis
via Fc receptor signaling and complement activation; the
role of antibody isotypes in atherogenesis is unclear, since
IgG is regarded as potentially proatherogenic, and IgM may
even play a protective role [47]. The last finding contradicts
with earlier data on atherogenicity of IgM-containing LDL-
CIC; however, till now there is no evidence that activation
of inflammation and foam cells formation should go in
parallel. It is not definitely known in which way foam
cells formed as a result of intracellular lipid accumulation
further drive the progression of atherosclerosis; there exists
the possibility of macrophages to acquire proinflammatory
phenotype after ingesting LDL-IgG through Fc gamma
receptor. However, it is known that LDL-CIC may induce
other atherosclerosis-related processes at the cellular level,
namely, excessive production of connective tissue matrix and
cellular proliferation [5, 36]. It has been shown recently that
in vitro produced immune complexes containing oxidized
LDL stimulate type IV collagen production by mesangial
cells, the effect being realized via Fc gamma receptors I
and III [48]. Such immune complexes also increased pro-
liferative activity of cultured human monocytes, and this
effect was mediated by cross-linking of Fc gamma recep-
tor I; a concentration-dependent production of monocyte
colony-stimulating factor was observed.These results offered
a novel mechanism by which an immune reaction toward
4 BioMed Research International
modified LDL can play a role in local accumulation of
macrophages in atherosclerotic lesions [49]. It is generally
approved that LDL-CIC effects are mediated via interaction
of immunoglobulin moiety with Fc receptors; since IgG and
IgM antibodies do not share the same receptors, this may be
the explanation for the abovementioned difference in uptake
of LDL bound either to IgG or to IgM.
It has been demonstrated that the lipoprotein-antibody
complexes prepared in vitro affect lipoprotein metabolism
in human fibroblasts and monocytes [50, 51] and facilitate
the accumulation of lipids in mouse macrophages [52].
Complexes of human LDL with polyclonal goat antibodies
against LDL induce the deposition of lipids in cultured SMC
of human aortic intima and peritoneal mouse macrophages
[3].
Taken together, these findings suggest that multiple-
modified desialylated LDL has immunogenic properties and
circulating immune complexes containing modified LDL
and anti-LDL autoantibodies are the blood components
responsible for primary cholesterol accumulation in vascular
cells. Since cholesterol accumulation is accompanied by
stimulation of other atherosclerotic manifestations at the
cellular level, it can be suggested that the presence of LDL-
containing complexes in the blood promotes the emergence
and development of atherosclerotic lesions in the vessel wall.
4. Diagnostic and Prognostic Value of
LDL-CIC in Atherosclerosis
Using a simple method of measurement of LDL-CIC level,
Orekhov et al. demonstrated that only LDL-CIC level and
the apo B/apo A-1 ratio contributed strongly to the discrimi-
nation between patients with coronary and/or extracoronary
atherosclerosis and those without stenosis [53]. In the same
study, total cholesterol, triglycerides, HDL cholesterol, apo B,
Lp[a], and apo A1 did not correlate with the presence and
severity of coronary and/or extracoronary atherosclerosis.
The authors concluded that LDL-CIC level might be the
most reliable marker of atherosclerosis as compared to other
parameters of lipid profile. LDL-CIC level was significantly
correlated also with the severity of coronary atherosclerosis,
and this biochemical parameter was proposed to be used as a
sensitive and specific marker for atherosclerosis, possessing
a high diagnostic value [5, 53, 54]. Salonen et al. have
reported that the titer of antibodies against MDA-modified
LDL in blood serum is associated with the progression of a
carotid atherosclerosis [55]. In the recent Epidemiology of
Diabetes Interventions and Complications (EDIC) Trial it
has been demonstrated that cholesterol and apolipoprotein
B content of immune complexes were significantly higher
in patients who showed progression of the internal carotid
IMT than in those showing no progression, regression,
or mild progression, and cholesterol content of immune
complexes was a significant positive predictor of internal
carotid IMT progression [56]. High cholesterol levels in CIC
are considered to be surrogate markers of modified LDL
associatedwith increased carotid intima-media thickness and
cardiovascular events. Lopes-Virella et al. have measured
oxidized LDL, advanced glycation end products-modified
LDL, and malondialdehyde-modified LDL in CIC, deter-
mined their relationship with increased carotid IMT in type
I diabetes, and compared the strength of the association with
that observed with conventional risk factors [57].
The most recent evaluation of diagnostic and predictive
role of LDL-CIC (immune cholesterol) as well as other lipid
parameters in early carotid atherosclerosis was carried out by
Sobenin at al. in two-year prospective study [58]. The rate of
atherosclerosis progression was estimated by high-resolution
B-mode ultrasonography as the increase in intima-media
thickness (IMT) of common carotid arteries. The patients
with elevated levels of LDL-CIC were characterized by sig-
nificantly higher levels of serum total and LDL cholesterol as
well as significantly increased mean and maximum intima-
media thickness of common carotid arteries. Cholesterol level
of LDL-CIC and serumLDL cholesterol were contingent with
the extent of early carotid atherosclerosis (𝑃 = 0.042 and 𝑃 =
0.049, resp.). Additionally, LDL-CICwas characterized by the
highest values of sensitivity and specificity as compared to
commonly used lipid parameters. Only LDL-CIC, but not any
other lipid parameter, was contingent with the progression
of early carotid atherosclerosis (𝑃 = 0.042) and also had the
highest levels of relative risk and odds ratio [59]. Normal level
of LDL-CIC (below 16.0 𝜇g/mL) was the only parameter that
predicted the absence of carotid atherosclerosis progression
for two following years at prognostic value of 78.3% (95%
CI, 67.1–87.3) [59]. Normal levels of serum total cholesterol,
LDL and HDL cholesterol, and triglycerides did not possess
statistically significant predictive values. Thus, in spite of
the absence of clinical manifestations of atherosclerosis,
the elevated level of LDL-CIC is associated with increased
intima-media thickness and can be regarded as a predictor
for higher risk of atherosclerosis development [58, 59].
In large meta-analyses of prospective population studies
in 165,544 participants without baseline CVD in 37 prospec-
tive cohorts (calendar years of recruitment: 1968–2007) with
up to 15,126 incident fatal or nonfatal CVD outcomes (10,132
CHD and 4994 stroke outcomes) during a median follow-up
of 10.4 years (interquartile range: 7.6–14 years), both baseline
LDL and HDL cholesterol levels were strong predictors
of both CHD and stroke [60]. The studies included in
this cited meta-analysis described conventional lipid profile
parameters, but not LDL-CIC, as predicting variables. How-
ever, the results of analysis demonstrate that the predictive
biomarkers in healthy population are not the same as those
for the diagnosis and prognosis of atherosclerosis; therefore,
diagnostic and prognostic role of LDL-CIC should be in focus
for further investigations in both nonatherosclerotic subjects
and preclinical and overt atherosclerosis.
5. Conclusions
On the basis of current data, it is possible to define the role of
lipoprotein-containing immune complexes in atherogenesis
(Figure 1). It can be supposed that LDL-CIC may play a
significant role in atherogenesis and are involved in the for-
mation of early atherosclerotic lesion. LDL-CIC can induce
massive cholesterol accumulation in cultured vascular cells
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Atherosclerotic manifestations at the cellular level
Lipidosis Proliferation Fibrosis
Formation of anti-LDL autoantibodies (predominately IgG)
LDL immunogenic modification (e.g., desialylation)
Native LDL
Interaction of LDL-CIC with vascular wall cells (Fc receptors)
Formation of LDL-containing immune complexes 
Figure 1: Schematic presentation of the role of lipoprotein-contain-
ing immune complexes in atherogenesis.
that leads to foam cell formation, cellular proliferation, and
extracellular matrix production [5, 36]. Modified LDL (e.g.,
desialylated, glycosylated, and oxidized LDL), which has an
atherogenic potential in contrast to native LDL, appears in
the blood. It stimulates atherosclerotic manifestations at the
arterial cell level, for example, by inducing the intracellular
lipid accumulation. Atherogenic modified LDL triggers the
production of anti-LDL autoantibodies which react with
LDL, leading to the formation of an LDL-containing immune
complex. Interaction of anti-LDL antibodies with modified
LDL increases their atherogenic potential. After forming an
immune complex with anti-LDL antibodies, the originally
nonatherogenic, native LDL becomes atherogenic (i.e., they
are capable of inducing intracellular lipid accumulation and
other atherosclerosis-related alterations). On entering the
subendothelial space of the arterial intima and interacting
with subendothelial cells, lipoprotein-containing immune
complexes may induce the whole spectrum of atherosclerotic
cellular perturbations. Titer of LDL-CIC in blood serum
significantly correlates with progression of IMT and has
the highest diagnostic value among other measured serum
lipid parameters. After removal of CIC, the sera lose their
atherogenic properties. Elevation of CIC-cholesterol seems to
be a characteristic feature of coronary atherosclerosis while
CIC-cholesterol might well be a possible risk factor.
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